Sign In
Buy DTIL
$6.04
-0.280 (-4.43%)
At Close: Jun 03, 2026
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
07:00am, Monday, 13'th May 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies f
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
08:15am, Wednesday, 08'th May 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene
Precision BioSciences to Report First Quarter Results on May 13, 2024
04:30pm, Tuesday, 07'th May 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies f
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies f
PHILADELPHIA--(BUSINESS WIRE)--iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver di
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
07:05am, Wednesday, 01'st May 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies f
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
04:15pm, Tuesday, 16'th Apr 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?
10:55am, Thursday, 11'th Apr 2024
After reaching an important support level, Precision BioSciences, Inc. (DTIL) could be a good stock pick from a technical perspective. DTIL recently experienced a "golden cross" event, which saw its 5
PHILADELPHIA--(BUSINESS WIRE)--iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver di
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know
10:56am, Tuesday, 02'nd Apr 2024
The consensus price target hints at a 407.9% upside potential for Precision BioSciences (DTIL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
07:51am, Tuesday, 02'nd Apr 2024
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
09:10am, Wednesday, 27'th Mar 2024
Precision BioSciences (DTIL) came out with a quarterly loss of $3.35 per share versus the Zacks Consensus Estimate of $3. This compares to loss of $7.81 per share a year ago.
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
06:45am, Wednesday, 27'th Mar 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies f
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
04:30pm, Wednesday, 20'th Mar 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies f
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
07:00am, Tuesday, 19'th Mar 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies f
